Assessing Quality of Life and AAD Research Considerations
Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.
Observing BSA Changes and Inflammation Resolution
Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.
Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock
Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.